Clinical Trial Update: Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® [Phase 4]

View source ↗

Summary

Phase 4 trial assessing predictive markers in children with growth hormone deficiency and Turner syndrome treated with SAIZEN. Results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency
• Turner Syndrome

Drugs mentioned

• Saizen (somatropin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Growth Hormone Deficiency, Turner Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2018-03-20